FTSE 100 stocks to buy and hold until 2030

Rupert Hargreaves highlights four FTSE 100 stocks that he’d buy and hold until 2030, considering their growth prospects.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding stocks to buy and hold for the next decade is incredibly challenging. Indeed, there’s no road map or shortcut I can use to find FTSE 100 stocks that’ll be around 10 years from now. 

However, by focusing on well-run companies with a sustainable competitive advantage, I think I can improve my chances of finding a long term buy-and-forget forget investment. 

There are a handful of companies in the FTSE 100 that appear as if they have these qualities. I’d buy all of them for that reason. 

FTSE 100 stocks to buy 

A great place to start looking for companies with a sustainable competitive advantage is the pharmaceutical sector. When drugs companies develop a treatment, they’re protected by exclusive manufacturing rights for an extended period. This is their primary competitive advantage. The companies can effectively charge what they like for these products while they’ve exclusive manufacturing rights. 

I think AstraZeneca is one of the most exciting pharmaceutical companies listed on the London market. It has been spending billions developing cancer treatments, and these treatments are now becoming a significant revenue stream for the group. 

Unfortunately, exclusive manufacturing rights don’t last forever. When they come to an end, companies like Hikma can produce the same product at a lower cost. That’s why I would buy both Astra and Hikma.

While Astra has a great portfolio of exclusive treatments, Hikma’s one of the world’s largest producers of generic drugs. Its competitive advantage is its size. It can produce these drugs at a much lower cost than competitors. As the global healthcare sector grows, I think the demand for these services will only expand. 

Both of these companies also have significant pricing power, but they could come under pressure from regulators to lower costs. If they do, this is one of the biggest challenges they may have to overcome. 

Long-term outlook

As well as the pharmaceutical companies outlined above, I’d also by Legal & General to hold in my portfolio FTSE 100 stocks.

This company is built for the long term. Its primary lines of business are pension and life insurance. In both of these markets, the group has to have a multi-generation perspective. Consumers buying life insurance and pension products need to be sure the organisation will still be around when they come to use them.

As such, management has to make decisions with long-term success in mind. This is a fantastic quality for a buy-and-forget investment, in my opinion. 

I’d also require distribution group Bunzl. Investors should never use past performance to guide future potential, but this company has successfully grown to become one of the UK’s largest corporations over the past few decades. 

Through a combination of acquisitions and organic growth, the enterprise has gone from strength to strength. It’s now a force to be reckoned with in the relatively uninteresting distribution industry. Management has no plans to change its strategy anytime soon. That’s why I think the company can continue to grow for the next decade. 

Unfortunately, while both of these businesses may be doing everything in their power to build a solid organisation, there’s always going to be the chance a hidden risk will emerge. This could hurt growth, or even lead to asset sales.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended Bunzl and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Will Lloyds shares rise 25% or 39% by this time next year?

Lloyds shares are expected to rebound after sinking to fresh multi-month peaks. Royston Wild considers the outlook for the FTSE…

Read more »

Modern suburban family houses with car on driveway
Investing Articles

£7,500 invested in Taylor Wimpey shares 18 months ago is now worth…

A raft of issues have been plaguing the housebuilding sector in the last year-and-a-half. How bad was the damage for…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£210 drip-fed into this 6.8%-yielding UK stock could lead to a £1,000 second income 

This FTSE 100 dividend stock has slumped nearly 11% inside two weeks, making it a worthy candidate to consider for…

Read more »

ISA Individual Savings Account
Investing Articles

ISA or SIPP? 2 factors to consider

As next month's ISA contribution deadline creeps up, our writer considers a couple of key differences between using a SIPP,…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is this 5.6% yielding dividend share a brilliant defensive bolthole as war rages?

Harvey Jones looks at a FTSE 100 dividend share with a brilliant record of delivering income and growth, and wonders…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 quality UK stocks trading below intrinsic value?

UK stocks have a reputation for being cheap, but could value investors be in dreamland with the opportunities being presented…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

£15,000 put into Greggs shares a year ago is worth this much now…

Greggs' sausage rolls may be tasty enough -- but its shares have left a bad taste in some investors' mouths…

Read more »

Investing Articles

FTSE 100 drops sharply — are serious bargains emerging in UK stocks?

Andrew Mackie looks at the FTSE 100 and explores how sharp falls, market volatility, and structural opportunities are reshaping the…

Read more »